“Effect of calcifediol treatment and best available therapy versus best available therapy on intensive care unit admission and mortality among patients hospitalized for COVID-19: A pilot randomized clinical study”

Pilot study (n=76) found fewer patients given calcifedol (25-hydroxyvitamin D) required admission to ICU vs untreated patients (2% vs 50%, p<0.001; OR 0.02, 95%CI 0.002-0.17). Authors state larger trials with groups properly matched will be required to show a definitive answer.

Source:

Journal of Steroid Biochemistry and Molecular Biology